SNDX

Syndax Pharmaceuticals, Inc.

SNDX | $21.62 -0.46% -0.51% 0

(0.0% 1d) (-1.4% 1m) (5.9% 1y) (0.0% 2d) (0.0% 3d) (-1.8% 7d) (68.61% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,836,953,807
http://www.syndax.com
Sec Filling | Patents | 35 employees

(US) Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

cancer

add to watch list Paper trade email alert is off

Press-releases

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Published: 2024-04-10 (Crawled : 20:00) - prnewswire.com
SNDX | $21.62 -0.46% -0.51% 0

Health Technology

| -1.77% | O: 0.45% H: 1.54% C: 0.95%

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Published: 2024-04-08 (Crawled : 11:00) - prnewswire.com
SNDX | $21.62 -0.46% -0.51% 0

Health Technology

| -3.35% | O: 3.35% H: 0.0% C: -1.34%
gment-101 positive leukemia trial

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Published: 2024-04-05 (Crawled : 20:00) - prnewswire.com
SNDX | $21.62 -0.46% -0.51% 0

Health Technology

| Email alert Add to watchlist
nasdaq pharmaceuticals grants

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
Published: 2024-03-28 (Crawled : 11:00) - prnewswire.com
SNDX | $21.62 -0.46% -0.51% 0

Health Technology

| -6.29% | O: 0.48% H: 4.36% C: 2.67%
gment-101 leukemia trial

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Published: 2024-03-28 (Crawled : 10:00) - globenewswire.com
ZYME | $9.09 -1.73% -1.76% 0

Health Technology

| -11.75% | O: 0.49% H: 2.13% C: 1.64%
SNDX | $21.62 -0.46% -0.51% 0

Health Technology

| -6.29% | O: 0.48% H: 4.36% C: 2.67%
BGNE S | $138.4 -2.05% -2.1% 10

Health Technology

| -10.76% | O: 1.24% H: 0.24% C: -0.39%

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Published: 2024-03-26 (Crawled : 20:00) - prnewswire.com
SNDX | $21.62 -0.46% -0.51% 0

Health Technology

| 0.84% | O: 1.63% H: 6.7% C: 5.87%
fda review treatment leukemia

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
Published: 2024-03-18 (Crawled : 12:00) - biospace.com/
SNDX | $21.62 -0.46% -0.51% 0

Health Technology

| -8.08% | O: -0.64% H: 0.77% C: -6.2%
commercial